This suggests that PDGFRβ in cerebrospinal fluid could serve as a potential biomarker for BBB dysfunction in AD, which still needs to be confirmed by more studies (Sagare et al., 2015). This evidence concerns the gene PDGFRB and Alzheimer disease.